This transcript has been edited for clarity. Hi, my name is Mamas Mamas. I'm professor of cardiology at Keele University, and welcome to Medscape. Continue reading →

As the use of edge-to-edge repair of mitral regurgitation (MR) ramps up, an expert consensus statement proposes volume standards, as well as operator and institutional requirements for all institutions providing treatment of mitral valve (MV) disease via transcatheter techniques. "These recommendations attempt to balance the need to support optimal quality outcomes with the goal of facilitating access to such innovative therapies an important paradigm for the development and implementation of future, less invasive approaches to structural heart disease," the writing committee states. Adherence to these recommendations, they say, will "maximize the chances that these therapies will be successfully incorporated into management pathways for patients with MV disease in the United States." The recommendations, published online December 16 in the Journal of the American College of Cardiology, are a joint effort of the American Association for Thoracic Surgery (AATS), the American College of Cardiology (ACC), the Society for Cardiovascular Angiography and Interventions (SCAI), and the Society of Thoracic Surgeons (STS). Continue reading →

................................ Continue reading →

InfoBionic was awarded the 2019 Frost and Sullivan North American Remote Cardiac Monitoring Technology Leadership Award for a reason: their cutting-edge technology and remarkable overall performance with full disclosure monitoring. As the year comes to a close, CEO Stuart Long looks ahead to additional product enhancements and the future of cardiac monitoring, building on the success of advancements realized this year Continue reading →

As more patients with cancer survive, the risk of cardiac complications due to the effects of therapies has become a concern to oncologists and cardiologists alike. Continue reading →

Long-term follow-up of the CvLPRIT trial shows that the risk of major adverse cardiovascular events continues to favor STEMI patients with obstructive multivessel disease who underwent complete revascularization compared with patients who had PCI of the culprit lesion only. Complete revascularization also was associated with a lower risk death and MI, with investigators reporting that after a median follow-up of 5.6 years, 10.0% of STEMI patients who underwent complete revascularization died or had an MI compared with 18.5% of patients randomized to PCI of the infarct-related artery alone (P < 0.0175). Continue reading →